NA89
NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED
04/04/2018
Back to search
Official data from USPTO
ALLERGAN
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: US
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
19
Latest update
04/04/2018
Classification
Registered
Trademark type
Word
Nice classes
5
Filing date
04/18/1997
Registration date
03/31/1998
Expiration date
-
Recommended action
Perform a full collision analysis and validate classes before any filing or trademark investment.
Next step
These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.
Complete case details
Structured fields from the responsible authority and the official record.
Status date
04/04/2018
Last transaction
04/04/2018
Responsible office
United States Patent and Trademark Office
Status code
800
Official register
Principal Register
First use anywhere
01/20/1950
First use in commerce
01/20/1950
Drawing code
1
Owner type
03
Owner location
IRVINE, CA
Examiner
WELLS, KELLEY
Law office
L50
Current location
GENERIC WEB UPDATE
Holders and representatives
Holders
ALLERGAN, INC.
ALLERGAN ELITE, INC.
Representatives
Susan J. Hinchey Allergan, Inc.
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
pharmaceutical formulationstopical antibioticsanti-inflammatoryanti-infectiveanti-glaucoma and decongestant formulations; sterile ointments; ocular wetting solutionsartificial tears and formulations for the treatment of minor ocular inflammations and allergic conditions; sterile ophthalmic saline solutions; contact lens cleaningdisinfectingwettingcushioningstoring and soaking formulations in solution or tablet form; pharmaceutical formulations for the therapeutic treatment of neurological disorders and muscle dystonias; dermatological formulationsmedicated dry skin lotions and creamsacne medications and medicated skin lighteners; pharmaceuticals for the treatment of actinic keratosisseborrhea and psoriasis; medicated shampoos and sunscreen preparations; pharmaceuticals for the treatment of actinic keratosisseborrhea and psoriasis
Publications
History of USPTO decisions and trademark events.
19 publications found
RNL2
REGISTERED AND RENEWED (SECOND RENEWAL - 10 YRS)
04/04/2018
89AG
REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED
04/04/2018
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
04/04/2018
E89R
TEAS SECTION 8 & 9 RECEIVED
03/22/2018
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
03/22/2018
RNL1
REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS)
09/18/2007
89AG
REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED
09/18/2007
PLGL
ASSIGNED TO PARALEGAL
09/14/2007
89AF
REGISTERED - COMBINED SECTION 8 (10-YR) & SEC. 9 FILED
08/28/2007
E89R
TEAS SECTION 8 & 9 RECEIVED
08/28/2007
CFIT
CASE FILE IN TICRS
05/22/2007
C15A
REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
07/01/2003
815F
REGISTERED - SEC. 8 (6-YR) & SEC. 15 FILED
04/01/2003
E815
TEAS SECTION 8 & 15 RECEIVED
04/01/2003
R.PR
REGISTERED-PRINCIPAL REGISTER
03/31/1998
PUBO
PUBLISHED FOR OPPOSITION
01/06/1998
NPUB
NOTICE OF PUBLICATION
12/05/1997
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
11/07/1997
Continuous trademark protection
Get notified about every new filing that threatens ALLERGAN or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.